v3.25.2
SCHEDULE OF INVESTMENT (Details) - USD ($)
Nov. 29, 2018
Jun. 11, 2018
Jun. 30, 2025
Sep. 30, 2024
Accounts Payable     $ 30,477 $ 29,669
Fair Value per Shares     $ 0.0155  
Zander Therapeutics Inc [Member]        
Investments, net     $ 17,733 17,333
Fair Value of Intellectual Property     300,000  
Prepaid Expenses     65,661  
Due from Employee      
Note Receivable     40,000  
Accrued Interest Receivable     35,000  
Investment Securities     258,255  
Convertible Note Receivable     10,000  
Accounts Payable     30,563  
Notes Payable     400,000  
Accrued Expenses Related Parties     162,011  
Notes Payable Related Party      
Accrued Expenses     647,072  
Enterprise Value     1,948,562  
Less: Total Debt     (1,239,646)  
Portion of Enterprise Value Attributable to Shareholders     708,916  
Zander Therapeutics Inc [Member] | Series M Preferred Stock [Member]        
Basis $ 134,971      
Fair Value 11,238      
Total Unrealized Gains/(Loss) $ (123,733)      
Zander Therapeutics Inc [Member] | Common Stock [Member]        
Investments, net     6,495 6,495
Basis   $ 87,608    
Fair Value   6,495    
Total Unrealized Gains/(Loss)   $ (81,112)    
Zander Therapeutics Inc [Member] | Series M Preferred Stock [Member]        
Investments, net     $ 11,238 $ 11,238